PRLD

In the past six months (approximately March 2026 - September 2026), Prelude Therapeutics received FDA clearance for its IND application for PRT13722, with a Phase 1 study expected in Q4 2026. The company reported Q1 2026 revenue of $4.58 million and a narrowed net loss of $10.4 million, followed by Q2 2026 revenue of $5.7 million and a narrowed net loss of $13.9 million. Prelude announced that its existing cash is expected to fund operations into the second quarter of 2028. In May 2026, D. Boral Capital initiated coverage with a 'Buy' recommendation, and analysts have raised fair value estimates due to optimism for PRT12396 and PRT13722. The stock showed a significant 313.51% increase from September 2025 to September 2026, but also experienced volatility, including a 26.07% fall in the last month and a 66% share price plunge in September 2026. The company participated in several investment and healthcare conferences, including the H.C. Wainwright 28th Annual Global Investment Conference, Goldman Sachs 47th Annual Global Healthcare Conference, and Jefferies Global Healthcare Conference.